SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Icahn Enterprises LP operates as holding company. It operates through following eight business segments: Investment, Automotive, Energy, Food Packaging, Metals, Real Estate, Home Fashion, and Pharma. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group LLC. The Energy segment holds ownership in CVR Energy, Inc., which owns majority interests in two separate operating subsidiaries, CVR Refining, LP and CVR Partners, LP. The Food Packaging segment holds ownership in Viskase Cos., Inc., which is engaged in the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Metals segment operates through PSC Metals, Inc., which engages in the business of collecting, processing, and selling ferrous and non-ferrous metals, as well as the processing and distribution of steel pipe and plate products in the Midwest and Southern U.S. The Real Estate segment consists of rental real estate, property development and resort activities. The Home Fashion segment operates through WestPoint Home LLC, which consists of manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operates through Vivus, Inc., a specialized pharmaceutical company. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

Icahn Enterprises is trending as investors discuss its high dividend yield and upcoming earnings report, focusing on whether the distribution will be maintained. Community members are analyzing Carl Icahn's investment strategies and potential impacts from holdings like CVR Energy, with some speculating about a potential short squeeze. The stock's volatile history and recent performance are driving both bullish and bearish sentiment within the investment community.

Akamai Technologies, Inc. engages in the provision of cloud services for delivering, optimizing, and securing content and business applications over the Internet. Its products include security, web performance, media delivery, and network operator. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

Akamai is trending following a Q3 earnings beat, driven by strong security and cloud computing growth, fueling discussions about the company's ongoing transformation. Community members are reacting positively to the results and raised guidance, with some analysts increasing price targets. The company's expansion in edge computing and AI is also a key talking point.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

PBR is trending as investors discuss the upcoming ex-dividend date and the potential payout amount, with some expressing excitement and others confusion regarding the details. Community members are also weighing whether to hold the stock long-term for dividends or take profits, considering factors like oil prices and the broader market context. Recent reports of earnings and leading the charge through key resistance is also driving interest.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending due to a mix of factors including record high ICE detainee populations and analyst upgrades, with community members weighing in on potential future price movements and government contracts. Discussions also involve share buybacks and comparing GEO's performance to similar companies, along with the impact of potential policy changes. Option traders are active, speculating on future gains with calls expiring in 2027.

LyondellBasell Industries NV engages in the refinery and production of plastic resins and other chemicals. It operates through the following segments: Olefins and Polyolefins-Americas; Olefins and Polyolefins-Europe, Asia, International; Intermediates and Derivatives; Advanced Polymer Solutions; Refining; and Technology. The Olefins and Polyolefins-Americas segment produces and markets olefins and co-products, polyethylene and polypropylene. The Olefins and Polyolefins-Europe, Asia, International segment also offers olefins and polyolefins. The Intermediates and Derivatives segment includes propylene oxide and its derivatives; oxyfuels and related products; and intermediate chemicals. The Advanced Polymer Solutions segment produces and markets compounding and solutions, such as polypropylene compounds, engineered plastics, masterbatches, colors and powders, engineered composites, and advanced polymers. The Refining segment refines heavy, high-sulfur crude oil and other crude oils of varied types and sources. The Technology segment develops chemical and polyolefin process technologies and manufactures and sells polyolefin catalysts. The company was founded in December 2007 and is headquartered in London, the United Kingdom.

LyondellBasell Industries NV - Ordinary Shares - Class A

LYB is trending due to recent price declines and upcoming earnings, with investors closely watching whether the company will maintain its dividend. The community is debating the stock's valuation, potential for a turnaround, and whether current prices present a buying opportunity or signal further downside. Discussions also include the broader impact of economic conditions and sector-specific challenges on LYB's performance.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending amid speculation about a potential breakup, with discussions focusing on whether this could unlock shareholder value or if debt concerns remain. The company's attractive dividend yield is also a key point, with some viewing it as a safe, inflation hedge play, while others express skepticism about long-term growth.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending amid discussions about its potential for a significant price increase and its role in the AI sector. Community members are actively debating entry points, potential targets, and whether it will participate in a broader altcoin rally. Some users are optimistic due to Fetch.ai's partnerships and treasury, while others express concerns about its past performance and integration with ASI.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors digest the company's recent earnings, with some highlighting a narrower-than-expected loss and revenue growth. The community is actively discussing the potential impact of Rivian's AI and robotics initiatives, as well as upcoming catalysts like Autonomy Day. Despite some skepticism, optimism is fueled by Amazon's significant stake and hopes for the R2 model's success.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending amidst a debate on its potential, with some traders calling it a "sucker coin" while others anticipate a rally, possibly fueled by staking rewards and broader market catalysts. Community chatter revolves around identifying entry and exit points, with strong opinions on both bullish and bearish scenarios. Sentiment appears mixed as some warn of further downside, while others look for a breakout.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Fresenius Medical Care is trending as the community discusses its Q3 earnings beat, driven by strong organic growth and margin improvements. A key talking point revolves around the potential impact of DefenCath, with some suggesting significant profit opportunities. Community members are also monitoring developments around TDAPA policy and potential CMS rule changes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on...

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent...

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.

Futures Flat Ahead Of Retail Sales, Trump-Putin Summit

Futures Flat Ahead Of Retail Sales, Trump-Putin Summit US equity futures are slightly higher , hovering near all time highs as traders bet that data on Friday will bolster the case for interest rate...

Precigen, Inc. (PGEN) said on Friday that the US Food and Drug Administration (FDA) has approved its immunotherapy Papzimeos for the treatment of adults with recurrent respiratory papillomatosis (RRP).Recurrent respiratory papillomatosis (RRP) is a rare condition where benign, wart-like tumors, called papillomas, grow in the respiratory tract, most commonly the larynx or the voice box. The disease can lead to severe voice disturbance, a compromised airway, and recurrent post-obstructive pneumonias. According to Precigen, there are about 27,000 adult RRP patients in the U.S.Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with RRP, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/precigen-announces-full-fda-approval-of-papzimeos-zopapogene-imadenovec-drba-the-first-and-only-approved-therapy-for-the-treatment-of-adults-with-recurrent-respiratory-papillomatosis-302530957.html">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PGEN">Precigen</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. Shares of the company traded 50% higher in the pre-market session at the time of writing.“With the landmark FDA approval of Papzimeos and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease," said CEO Helen Sabzevari. Management of RRP, the company said, previously primarily consisted of repeated surgeries that did not address its root cause.The FDA approval was supported by data from an open-label, single-arm study in adult patients with RRP in which 51% of study patients required no surgeries in the 12 months after treatment with Papzimeos. Further, the therapy was well-tolerated in the trial with no serious treatment-related adverse events.Precigen noted that no confirmatory clinical trial is required for the therapy, which is delivered via four subcutaneous injections over a 12-week interval. The company added that it will begin promoting Pazimeos immediately.H.C. Wainwright subsequently raised its price target on Precigen to $8.50 from $6 while keeping a 'Buy' rating on the shares. The firm expects the drug to generate sales of $1.1 billion in 2033 from $138 million in 2026.PGEN stock is up by 65% this year and by about 73% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/apple-stock-climbs-premarket-even-after-warren-buffett-s-berkshire-trims-stake/chsPjsBRdf9">Apple Stock Climbs Premarket Even After Warren Buffett’s Berkshire Trims Stake</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Precigen Stock Shot Through The Roof On Friday Morning – Here’s Why

The company stated that Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis. 

Equity

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 FDA Grants...

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at...

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md., Jan. 9, 2025 GERMANTOWN...

Small-cap, clinical-stage biopharma Precigen, Inc. ($PGEN) rallied on Monday following a regulatory update. The stock ended the session 28.47% higher at $0.9331 on more than six times the average volume.Germantown, Maryland-based Precigen announced the completion of the rolling submission for a biologic license application (BLA) for PRGN-2012, a gene therapy being investigated as a treatment option for adult patients with recurrent respiratory papillomatosis (RRP).RRP is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx, and it is caused by the human papillomavirus (HPV) 6 or HPV 11. It can prove fatal.&nbsp;Precigen said the BLA is now in the initial 60-day review period and the FDA will decide whether to accept the application for further review and set the Prescription Drug User Fee Act (PDUFA) date by this period.The company also noted that the application included a request for priority review, which, if granted, will reduce the review period from 10 months to six months.PRGN-2012 acts by eliciting immune responses directed against cells infected with HPV 6 or HPV 11. The company noted that there is no cure for the condition currently and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease.&nbsp;The regulatory application is supported by pivotal Phase 1/2 study results, which showed more than 50% of patients achieved complete response and more than 85% had a decrease in surgical interventions the year after the treatment.&nbsp;Helen Sabzevari, President and CEO of Precigen, "We look forward to working closely with the FDA on next steps now that we have completed the BLA submission and we are excited by the potential to bring PRGN-2012 to RRP patients as quickly as possible."'The executive also said, with the recent $79 million private placement of convertible preferred stock, the company has extended its cash runway into 2026, well beyond the potential commercial launch in the second half of 2025.<figure class="image"><img style="aspect-ratio:637/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/pgen_sentiment_0fbe6731dd.png" alt="pgen-sentiment.png" width="637" height="135"><figcaption>PGEN sentiment and message volume December 31, 2024, as of 3:36 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, sentiment toward Precigen flipped from ‘extremely bearish’ a day ago to ‘extremely bullish’ (96/100), the highest in a year. Message volume also spurted from ‘normal’ to ‘extremely high.’In a message posted on the PGEN stream on Stocktwits, a user said they looked ahead to a good 2025 for the company.&nbsp;<stembedurl>https://stocktwits.com/ASTAD13/message/598217372</stembedurl>If the company manages to get a priority voucher, it can resell it for $100 million, another noted.<stembedurl>https://stocktwits.com/Johnmtnb2018/message/598207700</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/analyst-picks-pegasystems-stock-among-top-10-tech-winners-of-2025/cJO1z97Rkm">Analyst Picks Pegasystems Stock Among Predicted Top 10 Tech Winners Of 2025: Retail Shares The Optimism</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally

Recurrent respiratory papillomatosis is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.09	--	--	N/A
Q2 '25	-$0.09	-$0.09	0.02%	BEAT
Q1 '25	-$0.18	-$0.18	--	EXPECTED
Q4 '24	-$0.05	-$0.07	-40.35%	MISSED
Q3 '24	-$0.09	-$0.09	-4.34%	MISSED

PGEN
Precigen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest PGEN News

PGENPrecigen Inc